146 related articles for article (PubMed ID: 33039808)
21. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Jin X; Chen Y; Chen H; Fei S; Chen D; Cai X; Liu L; Lin B; Su H; Zhao L; Su M; Pan H; Shen L; Xie D; Xie C
Clin Cancer Res; 2017 Sep; 23(17):5311-5319. PubMed ID: 28606918
[No Abstract] [Full Text] [Related]
22. miRNAs as novel biomarkers in the management of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2017 May; 55(5):715-736. PubMed ID: 26751899
[TBL] [Abstract][Full Text] [Related]
23. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
24. Next Generation Sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research.
Guelfi G; Cochetti G; Stefanetti V; Zampini D; Diverio S; Boni A; Mearini E
Sci Rep; 2018 May; 8(1):7111. PubMed ID: 29740090
[TBL] [Abstract][Full Text] [Related]
25. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
27. Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer.
Zhang J; Song Y; Zhang C; Zhi X; Fu H; Ma Y; Chen Y; Pan F; Wang K; Ni J; Jin W; He X; Su H; Cui D
Theranostics; 2015; 5(7):733-45. PubMed ID: 25897338
[TBL] [Abstract][Full Text] [Related]
28. Data-driven translational prostate cancer research: from biomarker discovery to clinical decision.
Lin Y; Zhao X; Miao Z; Ling Z; Wei X; Pu J; Hou J; Shen B
J Transl Med; 2020 Mar; 18(1):119. PubMed ID: 32143723
[TBL] [Abstract][Full Text] [Related]
29. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
Paziewska A; Mikula M; Dabrowska M; Kulecka M; Goryca K; Antoniewicz A; Dobruch J; Borowka A; Rutkowski P; Ostrowski J
Prostate; 2018 Feb; 78(3):178-185. PubMed ID: 29226351
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.
Bucay N; Sekhon K; Yang T; Majid S; Shahryari V; Hsieh C; Mitsui Y; Deng G; Tabatabai ZL; Yamamura S; Calin GA; Dahiya R; Tanaka Y; Saini S
Oncogene; 2017 May; 36(19):2667-2679. PubMed ID: 27893706
[TBL] [Abstract][Full Text] [Related]
31. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
32. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.
Torres-Ferreira J; Ramalho-Carvalho J; Gomez A; Menezes FD; Freitas R; Oliveira J; Antunes L; Bento MJ; Esteller M; Henrique R; Jerónimo C
Mol Cancer; 2017 Jan; 16(1):26. PubMed ID: 28143614
[TBL] [Abstract][Full Text] [Related]
33. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.
Hou Q; Bing ZT; Hu C; Li MY; Yang KH; Mo Z; Xie XW; Liao JL; Lu Y; Horie S; Lou MW
EBioMedicine; 2018 Jun; 32():234-244. PubMed ID: 29861410
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive biomarkers in prostate cancer.
Kontos CK; Adamopoulos PG; Scorilas A
Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550
[TBL] [Abstract][Full Text] [Related]
35. Identification of Key MicroRNAs and Mechanisms in Prostate Cancer Evolution Based on Biomarker Prioritization Model and Carcinogenic Survey.
Lin Y; Miao Z; Zhang X; Wei X; Hou J; Huang Y; Shen B
Front Genet; 2020; 11():596826. PubMed ID: 33519899
[No Abstract] [Full Text] [Related]
36. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
[TBL] [Abstract][Full Text] [Related]
37. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma.
Fadhil RS; Wei MQ; Nikolarakos D; Good D; Nair RG
PLoS One; 2020; 15(3):e0221779. PubMed ID: 32208417
[TBL] [Abstract][Full Text] [Related]
38. miR-148-3p and miR-152-3p synergistically regulate prostate cancer progression via repressing KLF4.
Feng F; Liu H; Chen A; Xia Q; Zhao Y; Jin X; Huang J
J Cell Biochem; 2019 Oct; 120(10):17228-17239. PubMed ID: 31104329
[TBL] [Abstract][Full Text] [Related]
39. Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p.
Kong Z; Wan X; Lu Y; Zhang Y; Huang Y; Xu Y; Liu Y; Zhao P; Xiang X; Li L; Li Y
J Cell Mol Med; 2020 Jan; 24(1):799-813. PubMed ID: 31733095
[TBL] [Abstract][Full Text] [Related]
40. Increased levels of serum miR-148a-3p are associated with prostate cancer.
Dybos SA; Flatberg A; Halgunset J; Viset T; Rolfseng T; Kvam S; Skogseth H
APMIS; 2018 Sep; 126(9):722-731. PubMed ID: 30160020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
